Pharvaris shares translational and clinical data at Bradykinin Symposium 2026
Pharvaris (PHVS) presented translational, nonclinical and clinical data at the Bradykinin Symposium 2026 in Zug, Switzerland.
ZUG, Switzerland, Sept.
03, 2026 (GLOBE NEWSWIRE) -- Pharvaris NASDAQ:PHVS, a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired ang…